Another possible biomarker for NAFLD is increased fibroblast growth factor 21, as was shown by meta-analysis, but there is not enough evidence for now to include it in routine screening [32]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.